Physician profile
Daniel V Spurlock
NPI 1013957257
$4,297.37
in general payments reported to CMS, 2019-2025
34 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $161 · 2021: $266 · 2022: $366 · 2023: $1,182 · 2024: $1,072 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $502.05 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $367.17 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $331.39 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Abbvie INC. | $296.10 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $291.39 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $277.79 | 2019-2024 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $228.54 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $182.68 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $164.88 | 2022-2024 | Azstarys |
| Indivior INC. | $155.36 | 2019-2024 | Sublocade |
| Neurocrine Biosciences, INC. | $145.02 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $129.04 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $121.49 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $113.84 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $97.42 | 2019-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $88.82 | 2023-2025 | Xelstrym |
| Harmony Biosciences LLC | $78.00 | 2023-2024 | Wakix |
| Jazz Pharmaceuticals INC. | $76.17 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $75.69 | 2019-2023 | Belsomra |
| Braeburn INC. | $75.03 | 2024 | Brixadi |
| Shire North American Group INC | $67.51 | 2019 | |
| Lundbeck LLC | $62.20 | 2023-2024 | Rexulti |
| Orexo US, INC. | $49.43 | 2019 | |
| Arbor Pharmaceuticals, INC. | $41.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $40.15 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $34.51 | 2022-2023 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $32.00 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $30.47 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $30.02 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $24.98 | 2019 | |
| Biogen, INC. | $24.62 | 2024 | |
| Eisai INC. | $23.51 | 2021 | |
| Almatica Pharma LLC | $20.84 | 2023 | Sertraline Hcl, Loreev Xr |
| Alfasigma USA, INC. | $17.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Spurlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.